Treatment of mice harboring subcutaneous Fc1245 c-CDCP1 tumors with 1 or 2 400 μCi doses of 177Lu-IgG58 resulted in significantly reduced tumor volume compared with vehicle control, with the 2-dose regimen approaching tumor stasis (Figure 6G and Supplemental Figure 15). This evidence concerns the gene CDCP1 and neoplasm.